Graphene oxide (GO) nanosheets were functionalized with Schiff base and reduced Schiff base. Covalent and non-covalent functionalized GO nanostructures have been tested for the removal of pesticides with different chemical structures and properties (e.g., Epoxiconazole, Dimethomorph, Cyprodinil, Chlorothalonil, Acetochlor, Trifluralin) from aqueous solutions. The structure and morphology characteristics of the prepared structures were analyzed using techniques such as solid-state nuclear magnetic resonance (SSNMR), Fourier transform infrared (FTIR) spectroscopy, X-ray diffraction (XRD), thermogravimetric analysis (TGA), scanning electron microscopy (SEM), and transmission electron microscopy (TEM). Results of the experiments showed that, although the non-covalent functionalization did not affect the adsorption properties of GO much, the covalent functionalization increased the adsorption capacity of GO against the mentioned pesticides.

(1) Background: Gastric cancer (GC) remains a major global health challenge due to its high heterogeneity and aggressive progression. The discovery of novel bioactive molecules with anticancer properties has, therefore, become a critical research focus. In this study, we synthesized and characterized 4,4′-(5,8-dioxa-2,11-diazadodecane-1,11-diene-1,12-diyl)diphenol (DODP) and evaluated its anticancer potential using molecular docking, bioinformatics, and experimental analyses. (2) Methods: The chemical structure of DODP was confirmed through ¹H and ¹³C NMR spectroscopy. Molecular docking was conducted to examine the interaction of DODP with apoptosis and cell cycle-related proteins (TP53, MDM2, and MYC) and the immune checkpoint marker CD274 (PD-L1). Cytotoxicity against AGS GC cells was determined using the MTT assay at concentrations ranging from 0.01 to 50 µM, and gene expression alterations were analyzed by quantitative polymerase chain reaction (qPCR) and bioinformatics evaluation. (3) Results: NMR data verified the successful synthesis of DODP. The docking results indicated strong binding affinity, especially with TP53 and CD274. DODP showed notable cytotoxicity after 72 h of exposure and induced upregulation of TP53, MYC, and CD274 and downregulation of MDM2 in AGS cells. Although the patterns were consistent with cell-based and bioinformatic analyses, significant discriminatory ability in blood samples was observed only for MYC (AUC = 0.651; p = 0.044). (4) Conclusions: DODP influenced apoptosis-associated transcriptional responses in GC, offering early mechanistic evidence that should be evaluated in more comprehensive biological models.

(1) Background: This study evaluates the anticancer potential of a newly synthesized azomethine-based compound, 6,6′,5,8-Dioxa-2,11-diazadodeca-1,11-diene-1,12-diyl)bis(4-bromo-2-methoxyphenol) (B-134-0), against osteosarcoma (SAOS-2) cells, focusing on its effects on apoptosis and DNA-damage-related gene expression. (2) Methods: B-134-0 was synthesized via condensation and tested at eight concentrations (0.5–100 μg/mL) for 24, 48, and 72 h. Cytotoxicity was assessed through MTT assay, and gene expression levels of TP53, RAD51, BRCA2, CASP2, MYC, MDM2, CDKN1A, ERCC1, ATR, and PRKDC were quantified through qPCR using the ΔΔ_Ct method. Molecular docking and DFT analyses were performed to explore structural stability and protein interactions. (3) Results: B-134-0 exhibited strong time-dependent cytotoxicity (IC₅₀: 71.58, 54.36, and 12.59 μg/mL at 24, 48, and 72 h, respectively) and significantly modulated the expression of cell cycle and DNA-repair-associated genes. The compound notably downregulated TP53, RAD51, CASP2, MYC, and MDM2, while CDKN1A and BRCA2 showed relative upregulation, indicating activation of the DNA damage response. Docking results revealed strong binding affinity with BRCA2 and CDKN1A, consistent with experimental findings. (4) Conclusions: These results indicate that B-134-0 exhibits potent anticancer activity by modulating DDR and apoptosis pathways, with strong molecular stability, suggesting its promise as a therapeutic candidate for osteosarcoma.